Recent studies have focused on the overlap of glucagon-like peptide-1|GIP|GCGR activator therapies and DA communication. While GLP stimulators are increasingly employed for addressing type 2 diabetes, their potential consequences on reinforcement circuits, specifically governed by DA networks, ar